Alnylam Pharma Reports Offering of $125M in Stock

Alnylam Pharmaceuticals, Inc.

, a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $125 million. All of the shares in the offering are to be sold by Alnylam.